Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 118

Heart Transplant Rejection Global Clinical Trials Review, H2, 2017

Summary

GlobalData’s clinical trial report, “Heart Transplant Rejection Global Clinical Trials Review, H2, 2017” provides an overview of Heart Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Heart Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Check Point Inhibitors, Interferons, and Interleukins), Therapy Area (Cancer, Autoimmune diseases& Inflammatory, Infectious Diseases), End User (Hospitals, Clinics ) – Global Forecast to 2025

 “The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025).” The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent. “Monoclonal antibodies are expected to witness high demand during the forecast period.” The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments.......
$4950

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Coronavirus Disease (COVID-19) : Epidemiology Analysis and Forecast – Apr 2020

Coronavirus Disease (COVID-19): Epidemiology Analysis and Forecast - Apr 2020 Summary First reported in Wuhan, China, in December 2019, now more than 846,200 confirmed cases of COVID-19 are spread across 187 countries worldwide. The US is now the most heavily affected country worldwide. Forecasts expect new cases to decrease for most countries in the top markets reporting cases except for Russia, which has not yet reached peak. People at risk for severe COVID-19 include population with underlying health problems, such as respiratory disease, cardiovascular disease, cancer, diabetes, some rare diseases, and diabetes. New analysis available this month for severely obese populations likely to be at risk for sever COVID-19. The global CFR has increased to more than 7%. The age groups most......
$1995

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Singapore

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analys......
$1995

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028

Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2028 Summary Age-related macular degeneration (AMD) is an eye condition that is characterized by the gradual deterioration of the macula, which is the oval-shaped area of the retina that is responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly. Classified by disease severity, AMD can be divided into three distinct stages. These are the early, intermediate, and late types of AMD. Out of the late forms, there are two further subtypes: dry (dAMD) and wet (wAMD). Dry AMD is evidenced by atrophy of the cells lining the retina, the accumulation of debris and the death of photoreceptors near the center of the fundus. Wet AMD is characterized by the grow......
$10995

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance – 2020 Edition

CMO Scorecard: Outsourcing of NDA Approvals and CMO Performance - 2020 Edition Summary This report is the 10th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance. CMO Scorecard is critical for benchmarking the performance of the CMO industry and the relative performance of major CMOs. Scope This report is required reading for - - CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions. - Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management. - Private equity investors that need a deeper understanding of the market to identify and value pote......
$4995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy